On March 4, 2026, Citius Oncology announced positive safety and efficacy results from a Phase 1 trial of LYMPHIR™ for treating high-risk relapsed or refractory diffuse large B cell lymphoma (DLBCL). This event is significant for the company and has a positive sentiment from an equity investor perspective.